Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Explore Imipenem/Cilastatin two-step dosing compared to 2 hours infusion in patients with
severe whether can obtain better results of the pharmacokinetic/pharmacodynamic, for clinical
rational use of antimicrobial agents, and provide theoretical support for optimizing dosage
regimen.